Fulgent Genetics (FLGT) reported $323M in revenue for fiscal 2025, +13.8% year on year. That ranks #2445 by revenue among 2853 SEC filers and #242 in Healthcare. It posted a net loss of −$60.5M for the same year. Revenue has grown 65.3% a year on average since 2014 ($1.3M then). The fiscal 2025 balance sheet shows $1.2B in total assets and $50.2M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $323M | +13.8% | FY20252025-12-31 |
| Gross profitGrossProfit | $131M | +22.1% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$91.1M | −$17.2M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$60.5M | −$17.8M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$102M | −$123M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $22.6M | −44.0% | FY20252025-12-31 |
| Total assetsAssets | $1.2B | −0.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.1B | −1.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $50.2M | −9.0% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $71.1M | −$24.8M | Open → |
| Q2 20262026-06-30 | $85.4M | −$29.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Fulgent Genetics, Inc.
- Ticker
- FLGT
- Exchange
- Nasdaq
- SIC classification
- Services-Medical Laboratories (8071)
- Fiscal year end
- 12-31
- CIK
- 0001674930
Filings
- 10-QJul 30, 2026Open filing →
- 10-QMay 1, 2026Open filing →
- 10-KFeb 27, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| InogenINGN | $349M | $22.7M |
| Castle BiosciencesCSTL | $344M | −$24.2M |
| Tactile Systems TechnologyTCMD | $330M | $19.1M |
| Fulgent GeneticsFLGT | $323M | −$60.5M |
| DocgoDCGO | $322M | −$196M |
| AngiodynamicsANGO | $320M | −$36.7M |
| CormedixCRMD | $312M | $163M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Fulgent Genetics — Key figures |url=https://companiesranked.com/en/company/fulgent-genetics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Fulgent Genetics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/fulgent-geneticsBibTeX
@misc{companiesranked-en-company-fulgent-genetics-2026,
author = {{CompaniesRanked}},
title = {{Fulgent Genetics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/fulgent-genetics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-079169 · February 27, 2026
{{cite web |title=Fulgent Genetics — Key figures — 10-K (0001193125-26-079169) |url=https://www.sec.gov/Archives/edgar/data/1674930/000119312526079169/flgt-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.